MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
TSX:MDP • CA58410Q2036
2.85 CAD
-0.01 (-0.35%)
Last: Feb 18, 2026, 07:00 PM
MDP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. MDP has only an average score on both its financial health and profitability. MDP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year MDP was profitable.
- In the past year MDP had a positive cash flow from operations.
- In multiple years MDP reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
- With a decent Return On Assets value of 0.25%, MDP is doing good in the industry, outperforming 69.70% of the companies in the same industry.
- The Return On Equity of MDP (0.73%) is better than 72.73% of its industry peers.
- The Return On Invested Capital of MDP (5.79%) is better than 81.82% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for MDP is in line with the industry average of 8.74%.
- The last Return On Invested Capital (5.79%) for MDP is well below the 3 year average (9.89%), which needs to be investigated, but indicates that MDP had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| ROIC | 5.79% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
- MDP has a better Profit Margin (0.37%) than 69.70% of its industry peers.
- MDP has a Operating Margin of 5.76%. This is in the better half of the industry: MDP outperforms 75.76% of its industry peers.
- MDP's Gross Margin of 53.01% is amongst the best of the industry. MDP outperforms 81.82% of its industry peers.
- MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.76% | ||
| PM (TTM) | 0.37% | ||
| GM | 53.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MDP is creating some value.
- Compared to 1 year ago, MDP has more shares outstanding
- The number of shares outstanding for MDP has been increased compared to 5 years ago.
- Compared to 1 year ago, MDP has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of 0.57, we must say that MDP is in the distress zone and has some risk of bankruptcy.
- MDP has a better Altman-Z score (0.57) than 66.67% of its industry peers.
- MDP has a debt to FCF ratio of 1.57. This is a very positive value and a sign of high solvency as it would only need 1.57 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 1.57, MDP belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
- A Debt/Equity ratio of 0.00 indicates that MDP is not too dependend on debt financing.
- MDP has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. MDP outperforms 87.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.57 | ||
| Altman-Z | 0.57 |
ROIC/WACC0.62
WACC9.28%
2.3 Liquidity
- MDP has a Current Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 0.83, MDP is doing worse than 84.85% of the companies in the same industry.
- MDP has a Quick Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Quick ratio of MDP (0.38) is worse than 84.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.38 |
3. Growth
3.1 Past
- The earnings per share for MDP have decreased strongly by -88.89% in the last year.
- The Revenue has decreased by -0.63% in the past year.
- MDP shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.82% yearly.
EPS 1Y (TTM)-88.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-317.78%
Revenue 1Y (TTM)-0.63%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-5.94%
3.2 Future
- MDP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
- The Revenue is expected to grow by 11.22% on average over the next years. This is quite good.
EPS Next Y-188.37%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue Next Year-8.08%
Revenue Next 2Y4.36%
Revenue Next 3Y7.5%
Revenue Next 5Y11.22%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 285.00 indicates a quite expensive valuation of MDP.
- Compared to the rest of the industry, the Price/Earnings ratio of MDP indicates a somewhat cheap valuation: MDP is cheaper than 69.70% of the companies listed in the same industry.
- MDP is valuated expensively when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 10.33, which indicates a very decent valuation of MDP.
- MDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDP is cheaper than 84.85% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of MDP to the average of the S&P500 Index (28.16), we can say MDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 285 | ||
| Fwd PE | 10.33 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 87.88% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, MDP is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.03 | ||
| EV/EBITDA | 5.29 |
4.3 Compensation for Growth
- MDP has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as MDP's earnings are expected to grow with 77.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.9%
EPS Next 3Y77.1%
5. Dividend
5.1 Amount
- MDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MDP (2/18/2026, 7:00:00 PM)
2.85
-0.01 (-0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2026-02-11
Earnings (Next)N/A N/A
Inst Owners3.25%
Inst Owner ChangeN/A
Ins Owners7.59%
Ins Owner ChangeN/A
Market Cap92.40M
Revenue(TTM)104.10M
Net Income(TTM)381.00K
Analysts82.5
Price Target6.32 (121.75%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.5%
Min EPS beat(2)0.99%
Max EPS beat(2)144%
EPS beat(4)4
Avg EPS beat(4)68.3%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)6
Avg EPS beat(8)45.18%
EPS beat(12)9
Avg EPS beat(12)93.03%
EPS beat(16)11
Avg EPS beat(16)69.35%
Revenue beat(2)0
Avg Revenue beat(2)-2.42%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.53%
Revenue beat(12)4
Avg Revenue beat(12)-1.12%
Revenue beat(16)8
Avg Revenue beat(16)1.52%
PT rev (1m)0.35%
PT rev (3m)0.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-500%
EPS NY rev (1m)-27.27%
EPS NY rev (3m)-460%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 285 | ||
| Fwd PE | 10.33 | ||
| P/S | 0.65 | ||
| P/FCF | 5.03 | ||
| P/OCF | 4.17 | ||
| P/B | 1.29 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.29 |
EPS(TTM)0.01
EY0.35%
EPS(NY)0.28
Fwd EY9.68%
FCF(TTM)0.57
FCFY19.88%
OCF(TTM)0.68
OCFY24%
SpS4.38
BVpS2.21
TBVpS-1.04
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.7
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| ROCE | 8.05% | ||
| ROIC | 5.79% | ||
| ROICexc | 6.63% | ||
| ROICexgc | N/A | ||
| OM | 5.76% | ||
| PM (TTM) | 0.37% | ||
| GM | 53.01% | ||
| FCFM | 12.92% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.57 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 30.83% | ||
| Cap/Sales | 2.68% | ||
| Interest Coverage | 1.96 | ||
| Cash Conversion | 107.99% | ||
| Profit Quality | 3530.97% | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.38 | ||
| Altman-Z | 0.57 |
F-Score5
WACC9.28%
ROIC/WACC0.62
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-317.78%
EPS Next Y-188.37%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-0.63%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-5.94%
Revenue Next Year-8.08%
Revenue Next 2Y4.36%
Revenue Next 3Y7.5%
Revenue Next 5Y11.22%
EBIT growth 1Y-53.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.54%
EBIT Next 3Y65.62%
EBIT Next 5Y48.64%
FCF growth 1Y3.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.81%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MDP.CA.
What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 6 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.